M&A Deal Summary

Adynxx Acquires Alliqua

On October 12, 2018, Adynxx acquired medical products company Alliqua

Acquisition Highlights
  • This is Adynxx’s 1st transaction in the Medical Products sector.
  • This is Adynxx’s 1st transaction in the United States.
  • This is Adynxx’s 1st transaction in Pennsylvania.

M&A Deal Summary

Date 2018-10-12
Target Alliqua
Sector Medical Products
Buyer(s) Adynxx
Deal Type Merger
Advisor(s) H. C. Wainwright & Co., LLC (Financial)
Haynes and Boone (Legal)

Target

Alliqua

Langhorne, Pennsylvania, United States
Alliqua provides a custom manufacturing solution to partners in the medical device; cosmetics; and OTC industry, utilizing its proprietary hydrogel technology. Alliqua's electron beam production process, located at its 16,500 square foot GMP manufacturing facility in Langhorne, Pa., allows Alliqua to custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for the pharmaceutical and cosmetic industries.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Adynxx

San Francisco, California, United States

Category Company
Sector Life Science
DESCRIPTION

Adynxx is a clinical-stage pharmaceutical company developing a potentially transformative technology platform addressing pain at its molecular roots – treating the development of pain following surgery or trauma and established chronic pain syndromes. Adynxx's approach is to transform pain management by approaching pain as a disease rather than a symptom. Adynxx is based in San Francisco, California.


DEAL STATS #
Overall 1 of 1
Sector (Medical Products) 1 of 1
Type (Merger) 1 of 1
State (Pennsylvania) 1 of 1
Country (United States) 1 of 1
Year (2018) 1 of 1